[Wish to conceive while using infliximab: considerations]

Area of Science:

• Reproductive medicine
• Gastroenterology
• Immunology

Background:

• Inflammatory bowel disease (IBD) impacts women of childbearing age, posing challenges for conception and pregnancy.
• IBD and its treatments can affect maternal health and fetal development.

Observation:

• A 30-year-old woman with Crohn's disease in remission for 2 years on infliximab desired conception.
• She received an individualized risk assessment, and infliximab was continued until 22 weeks gestation.
• Her pregnancy was monitored, resulting in the birth of a healthy neonate at 38 weeks.

Findings:

• Continuing infliximab under medical supervision during pregnancy is feasible.
• Individualized risk-benefit analysis is crucial for managing IBD medications in pregnant women.

Implications:

• This case highlights the importance of preconceptional counseling and ongoing risk assessment for IBD patients planning pregnancy.
• Maintaining disease remission and optimizing medication management can lead to successful pregnancy outcomes.